Daily Biotech Movers — 2026-08-07: Guidance Sets the Tape in a Broad Risk-On Rally

Friday, August 7, 2026 was the strongest biotech tape of the earnings season so far — and it was decided almost entirely by the forward look. The S&P 500 ETF gained +0.61%, but biotech ran well ahead of it: XBI added +1.86%, IBB +2.46%, and XLV +0.75%. Within our coverage universe, 398 names finished higher and 164 lower — a 2.4-to-1 advance ratio — out of 562 companies showing a directional move among 581 tracked. The mean move was +1.65%, the median +1.43%, and the standard deviation 6.45%. 149 names were anomaly-flagged (moves of at least 5% or volume at least 2x normal), of which 133 moved at least 5% on price — and five of the six biggest prints were same-day reactions to Q2 disclosures filed in the past 36 hours.

The leaderboard is a study in guidance asymmetry. On the upside, AVITA Medical (+63.58%) reported record Q2 results, raised its 2026 revenue guidance, and guided to fourth-quarter cash-flow breakeven — a name that had been stuck in analyst-Hold purgatory through July re-rated 63% in a single session. OmniAb (+37.50%) more than tripled quarterly revenue on partner milestones and raised its full-year outlook, closing at a 52-week high. Arcturus Therapeutics (+21.88%) beat Q2 estimates by $0.16 per share. On the downside, CVRx (-59.76%) cut its 2026 revenue outlook sharply despite a top-line beat, QuidelOrtho (-24.72%) lowered full-year guidance and withdrew free cash flow guidance, and Tenon Medical (-22.02%) slid mechanically into a 1-for-35 reverse stock split. The pattern from Wednesday and Thursday held and hardened: the market is not paying for beats; it is paying for raised guidance, cash-flow milestones, and balance-sheet credibility.

The Distribution

Measure	August 7 reading
Tracked / priced	581
Directional moves	562
Up / down	398 / 164
Mean / median	+1.65% / +1.43%
Standard deviation	6.45%
Anomaly-flagged	149
Price moves of at least 5%	133

Breadth was decisively positive at 2.4 advancers per decliner — the strongest internals since the June catapult day — and mean and median both sat firmly in positive territory. The 149 anomaly flags include 133 names that moved at least 5% on price; the remaining 16 are volume-only anomalies (2x+ volume on a smaller price move). Against Thursday’s 6.04% standard deviation, today’s 6.45% is the widest dispersion of the week, but the center of the distribution tells the real story: a risk-on day where the tails were still earnings-driven. The index trio (SPY +0.61%, XBI +1.86%, IBB +2.46%) confirms the move was biotech-led, not broad-beta — capital rotated into the sector on Friday, then sorted names by the quality of their forward guidance.

The 6 Classes of Mover Signal

The six signal classes separate a fundamental repricing from a technical event. On August 7, four of the six top movers are Class 2 single-stock fundamental events, one is Class 1 mechanical, and one is a Class 5 prior-cycle unwind — an earnings-season profile with one structural outlier.

1. Halt-release or reverse-split-adjacent. TNON (Tenon Medical, -22.02% at $0.13) is the day’s lone Class 1 print: the company announced a 1-for-35 reverse stock split on August 6 (Seeking Alpha — Tenon Medical announces 1:35 reverse stock split). A pre-split price of $0.13 with below-average volume (0.65x) and five-day momentum of -33.8% is the textbook mechanical signature — percentage moves on a sub-$0.20 ticker amplify pre-split flows, and no fresh negative news accompanied the slide.

2. Single-stock clinical or regulatory event. The clean-catalyst bucket is today’s center of gravity, but the triggers were financial, not scientific. RCEL, OABI, ARCT, CVRX, and QDEL all printed on same-day or previous-evening Q2 disclosures with institutional volume confirmation — the earnings-season analog of a clinical readout, where the “data” is revenue, guidance, and cash.

3. Buyout or strategic capital. No top-six print is a pure Class 3 event today. The closest analog is AVITA Medical’s re-rating, which has a strategic-capital flavor — a record quarter plus an explicit Q4 cash-flow breakeven milestone converts a dilution-averse story into a self-funding one, and the 14.26x volume says institutions were the buyer, not the momentum crowd.

4. Sector rotation. The sector read is the widest of the week and unmistakably risk-on. Leaders included Genetics & Genomics (+6.44% across 7 names, led by Natera’s +21.37%), Drug Delivery/Formulation (+5.08% across 28), Antibodies (+4.01% across 40), and Cannabis-related (+3.76% across 5). The laggards were Devices — Implants (avg -6.53% across 10 — but a median of +2.16%, meaning CVRx’s -59.76% alone dragged the category average), Devices — Miscellaneous (-0.55%), Devices — Imaging (-0.34%), and Generic Drugs (-0.37%). The read is beta-plus-selection: XBI outperformed XLV by over a full point for the second straight session, and within the sector the money chased growth stories with improving forward guidance (drug delivery, antibodies, genomics) while shunning device names with execution questions.

5. Sell-the-news / prior-cycle profit-taking. AMIX (Autonomix Medical, -17.50% on 0.10x volume) is the day’s defining Class 5 print — the latest leg of the squeeze-and-unwind saga that began with the August 4 patent-driven spike: five-day momentum of +191.9% against a -17.5% session on a tenth of normal volume is a low-float unwind with no fresh news attached, the mirror image of Thursday’s dilution-reversal framing. Prior-cycle catalyst — flagged.

6. Stealth accumulation / distribution. ALXO (ALX Oncology) traded 7.59x normal volume on a -0.47% move, BOLD (Boundless Bio) 3.54x on +1.76%, APYX (Apyx Medical) 3.52x on -2.64%, and TBPH (Theravance Biopharma) 3.25x on +0.06%. All four are unresolved flow signals — flat price, heavy tape, direction to be resolved over the next one to three sessions.

Top 3 Winners — What Drove Them

RCEL — AVITA Medical — +63.58% on 14.26x volume

AVITA Medical closed at $7.77 — a new 52-week high (intraday $8.07) — after trading 7.28 million shares, or 14.26x its 30-day average, with five-day momentum of +76.6%. The catalyst was the August 6 after-close Q2 report: record second-quarter results, raised full-year 2026 revenue guidance, and a public expectation of fourth-quarter cash-flow breakeven (Business Insider — AVITA Medical reports Q2, raises 2026 revenue guidance, expects Q4 cash flow breakeven; MSN — Avita Medical shares surge after record second-quarter performance; MarketBeat — AVITA Medical Q2 earnings call highlights). The RECELL franchise had been quietly re-rating since mid-July as analysts backed its momentum (Yahoo Finance — AVITA Medical stock sees fair-value lift as analysts back RECELL momentum), and Friday added a Canaccord Genuity Growth Conference participation notice (GlobeNewswire — AVITA Medical announces participation at Canaccord Genuity Growth Conference). The 34.7% intraday range ($5.99-$8.07) on 14x volume reads as short-covering into a guidance raise on a name that had been sitting in downgrade-to-Hold territory as recently as July 25. Signal class: Class 2 single-stock fundamental event (earnings beat + guidance raise), new 52-week high.

OABI — OmniAb — +37.50% on 5.07x volume

OmniAb closed at $3.08 — a new 52-week high (intraday $3.12) — on 2.68 million shares, or 5.07x normal volume, with five-day momentum of +55.6%. Q2 revenue of $13.4 million versus $3.9 million a year earlier — milestone payments from partnered antibody-discovery programs more than tripling the top line — narrowed the net loss to $5.9 million from $15.9 million and supported a raised full-year 2026 revenue outlook of $32-$36 million plus an improved year-end cash position (MarketBeat — OmniAb Q2 earnings call highlights; Yahoo Finance UK — OmniAb Q2 2026 earnings call highlights; Seeking Alpha — OmniAb Q2 2026 earnings call transcript). The platform story — OmniRat, OmniChicken, OmniMouse and the OmniDeep AI tools — finally has a fundamental base after a long post-spinout drawdown, and closing at a 52-week high on 5x volume gives the milestone narrative institutional confirmation. Signal class: Class 2 single-stock fundamental event (Q2 beat + guidance raise), new 52-week high.

ARCT — Arcturus Therapeutics — +21.88% on 2.68x volume

Arcturus Therapeutics closed at $7.41 on 1.46 million shares — 2.68x its 30-day average — with five-day momentum of +28.6%, extending a rally that began after its August 6 Q2 release, which beat analyst estimates by $0.16 per share (MarketBeat — Arcturus Therapeutics announces earnings results, beats estimates by 0.16 EPS; MarketBeat — ARCT Q2 2026 earnings report). Friday’s session cleared the 50-day moving average ($6.77) on roughly 3.3x normal volume — a same-day earnings follow-through on the LUNAR/STARR mRNA platform (ARCT-032 for cystic fibrosis and ARCT-810 for OTC deficiency are both in Phase 2). The stock remains near the bottom of its 52-week range ([$5.50, $24.17]) — the day was a beat-driven bounce off a long drawdown, not a breakout. Signal class: Class 2 single-stock fundamental event (earnings beat, follow-through).

Top 3 Losers — What Drove Them

CVRX — CVRx — -59.76% on 19.67x volume

CVRx collapsed to $2.39 — at its 52-week low (intraday $2.30) — on 14.77 million shares, or 19.67x normal volume — the heaviest print on the entire board — with five-day momentum of -53.8%. The August 6 Q2 report carried a top-line beat — $15.7 million in revenue at 87% gross margins — but a $0.53 per-share loss slightly worse than estimates, a sharp cut to the full-year 2026 revenue outlook with softer Q3 guidance, and cash-burn concerns that dominated the call (Benzinga — CVRx stock is falling after Q2 results, lower 2026 outlook; Simply Wall St — CVRx stock reels from guidance cut and cash-burn fears). Friday brought a downgrade wave — Lake Street cut to Hold with a $3.50 target (MarketBeat) and Craig-Hallum cut to Hold with a $4.00 target (MarketBeat) — plus a Johnson Fistel investor-solicitation notice tied to the guidance cut and sales-execution disclosures (GlobeNewswire via MarketChameleon). The Barostim heart-failure neuromodulation story went from an $18.00 IPO (June 2021) to a $63 million market cap on a sales-execution miss. Signal class: Class 2 single-stock fundamental negative (guidance cut + downgrades), new 52-week low.

QDEL — QuidelOrtho — -24.72% on 3.19x volume

QuidelOrtho fell to $12.29 on 4.89 million shares — 3.19x normal volume — with five-day momentum of -26.7%. The August 6 Q2 report showed total revenue of $631 million, up 2% on a constant-currency basis — but management lowered the full-year outlook and withdrew free cash flow guidance amid continued China pressure and a softer respiratory testing environment (MarketBeat — QuidelOrtho Q2 earnings call highlights; PR Newswire — QuidelOrtho reports second quarter 2026 financial results). The 5d of -26.7% shows the slide began before Friday’s session, but the guidance cut and the FCF withdrawal converted a modest beat into a -24.7% repricing on 3x volume — a $1.05 billion trailing net loss and a forward P/E of 12.3 left no room for an outlook miss. Signal class: Class 2 single-stock fundamental negative (guidance cut + FCF guidance withdrawal).

TNON — Tenon Medical — -22.02% on 0.65x volume

Tenon Medical dropped to $0.13 on 2.58 million shares — 0.65x its 30-day average — with five-day momentum of -33.8%, in a mechanical continuation of its announced 1-for-35 reverse stock split (Seeking Alpha — Tenon Medical announces 1:35 reverse stock split). At a pre-split price of $0.13 with below-average volume, the move carries the Class 1 signature precisely: percentage moves on a sub-$0.20 ticker amplify mechanical pre-split flows, and the 5d of -33.8% confirms a multi-session slide into the split rather than a fresh negative catalyst. The Catamaran SI-joint fusion franchise is a real commercial product, but at this price the tape is all corporate-action mechanics. Signal class: Class 1 halt-release / reverse-split-adjacent (1-for-35 reverse split).

The Cross-Cutting Pattern

Friday’s pattern was guidance asymmetry inside a broad risk-on day: the market bid up companies that raised or protected their forward look and buried companies that cut it — with the beta backdrop amplifying both directions. RCEL (+63.58%) raised guidance and added a cash-flow milestone — the cleanest possible forward signal — and printed a 52-week high on 14x volume. OABI (+37.50%) raised revenue guidance and the year-end cash outlook, closing at a 52-week high. ARCT (+21.88%) beat by a wide EPS margin, and while it did not raise, the beat was enough to clear the 50-day average. On the losing side, CVRX (-59.76%) beat revenue but cut the year — and got cut nearly 60% for it. QDEL (-24.72%) grew constant-currency revenue but lowered the year and withdrew the cash-flow target. The symmetry is brutal and consistent with Wednesday and Thursday: winners delivered good forward news; losers delivered disappointing forward news, regardless of the size of the headline beat.

The sector data tells the same story from the other side. Genetics & Genomics (+6.44%) had Natera’s +21.37% diagnostics surge; Drug Delivery/Formulation (+5.08%) had RCEL’s raise; Antibodies (+4.01%) had OABI’s milestone quarter. The Devices — Implants average of -6.53% is a CVRX artifact (the category median was +2.16%). The XBI (+1.86%) versus XLV (+0.75%) versus SPY (+0.61%) trio shows biotech outperforming broad equities for a second straight session — this is no longer a rotation within healthcare, it is capital rotating into biotech and then sorting by guidance. The stealth tape deserves one line: ALXO’s 7.59x volume on -0.47% is the day’s most interesting unresolved flow signal, with BOLD (3.54x, +1.76%) and TBPH (3.25x, +0.06%) as quieter companions.

The 5 Data Points That Matter

1. % change vs sector mean. The winners beat their sectors by wide margins — RCEL +63.58% vs a Drug Delivery/Formulation sector averaging +5.08%, OABI +37.50% vs Antibodies at +4.01%, ARCT +21.88% vs a Biologics-heavy tape at +1.27%. The losers undercut theirs — CVRX -59.76% dragged its own category average below zero. Company-specific disclosures, not sector beta, drove every print that mattered.

2. Volume ratio. The winner volume was decisive: RCEL 14.26x (short-covering into a raise), OABI 5.07x, ARCT 2.68x. The loser volume was even more so: CVRX 19.67x — the heaviest print on the board, institutional distribution out of the Barostim story — and QDEL 3.19x. TNON’s 0.65x is the tell that its move is mechanical: a sub-$0.20 name needs no volume to fall.

3. 5-day momentum. Winners were accelerating: RCEL +76.6%, OABI +55.6%, ARCT +28.6%. The losers were sliding: CVRX -53.8%, QDEL -26.7%, TNON -33.8%. The standout is AMIX at +191.9% 5d on a -17.5% day — the squeeze unwind is still working its way out.

4. 52-week range. RCEL at $7.77 closed above its prior range top ($8.07 intraday) — a breakout on 14x volume. OABI at $3.08 closed at a 52-week high. ARCT at $7.41 sits near the bottom of [$5.50, $24.17] — a bounce, not a breakout. CVRX at $2.39 closed at its 52-week low; QDEL at $12.29 sits in the lower third of [$9.92, $35.58]; TNON at $0.13 is off the measurable range entirely. Where a name sits in its range separates the genuine repricing (RCEL, OABI) from the dead-cat bounce (ARCT) and the structural decay (CVRX, QDEL).

5. Cash / dilution context. The winners were balance-sheet stories in the best sense: RCEL guided to Q4 cash-flow breakeven (the self-funding milestone), OABI raised its year-end cash outlook, ARCT beat with a leaner cost base. The losers were the opposite: CVRx faces cash burn into a cut outlook at a $63 million market cap, QDEL withdrew its FCF target while carrying a $1.05 billion trailing loss, and TNON’s reverse split is dilution mechanics by another name. On a tape where the forward look decided everything, cash and share-supply signals were the tiebreakers again.

What This Synthesis Will and Won’t Tell You

This synthesis is a one-day reading, and it should be read as such. It tells you what moved and why — the 149 anomaly-flagged names, the six top movers, the class of signal behind each, and the cross-cutting pattern: in the second week of Q2 reporting season, raised guidance and cash-flow milestones decide the tape, and a broad risk-on day simply amplifies that sorting. It does not tell you what happens next: RCEL’s 52-week-high breakout can follow through or fade as the breakeven quarter approaches; OABI’s milestone cadence can accelerate or pause with partner timelines; CVRX’s -60% repricing can find a floor or keep sliding if the sales-execution disclosures extend; QDEL’s guidance cut needs quarters, not days, to prove out.

The honest limits: the why-investigation covers the six data-defined top movers only — mid-cap prints elsewhere in the top 15 (Natera +21.37% on 2.61x volume, Halozyme +20.24% on 3.86x volume, Tandem Diabetes +19.11% on 2.74x volume) are noted but not deep-dived, and some of those carry their own earnings-driven stories. Sector categories are broad, and small-n buckets (Cannabis-related, n=5; Generic Drugs, n=5) should be read with skepticism. And a single day’s median of +1.43% says nothing about the week, the quarter, or the year — the durable signal here is not any one print but the pattern that has now held for three consecutive sessions: when the top winners raise guidance and the top losers cut it, the market is telling you it cares about the forward look, not the headline. That is a tape worth watching through the rest of earnings season — and the first true risk-on session of the cycle is the one that deserves the closest scrutiny.

---

This is editorial analysis, not investment advice. Single-day returns reflect closing prices on 2026-08-07 and will change with market conditions, clinical readouts, financing terms, and regulatory events. Microcap and clinical-stage names can experience rapid reversals; readers should review the underlying disclosures before drawing conclusions about momentum durability.

Sources: Business Insider on AVITA Medical’s Q2 results and guidance raise; MSN on AVITA Medical’s record Q2 surge; MarketBeat on AVITA Medical’s Q2 call; GlobeNewswire on AVITA Medical’s Canaccord conference participation; MarketBeat on OmniAb’s Q2 call; Yahoo Finance UK on OmniAb’s Q2 highlights; Seeking Alpha on OmniAb’s Q2 transcript; MarketBeat on Arcturus’ Q2 EPS beat; Benzinga on CVRx’s Q2 slide; Simply Wall St on CVRx’s guidance cut; MarketBeat on Lake Street’s CVRx downgrade; MarketBeat on Craig-Hallum’s CVRx downgrade; MarketBeat on QuidelOrtho’s Q2 call; PR Newswire on QuidelOrtho’s Q2 results; Seeking Alpha on Tenon Medical’s 1:35 reverse split; company IR pages and SEC filings; market data compiled from public exchange quotes.